Hepatitis E Diagnostic Tests Market Size, Share, Growth, and Industry Analysis, By Type (ELISA HEV IgM Test kits, ELISA HEV IgG Test Kits, RT-PCR Test Kits) By Application (Hospitals, Diagnostic Laboratories, Research Centers, Point of Care) and Regional Insights and Forecast to 2034

•   
•   
  

  Download Free Sample to learn more about this report

    

HEPATITIS E DIAGNOSTIC TESTS MARKET OVERVIEW

The global Hepatitis E Diagnostic Tests market size was USD 0.044 billion in 2025 and is projected to reach USD 0.053 billion by 2034, exhibiting a CAGR of 2.1% during the forecast period.

The current diagnostic tests of Hepatitis E in the global market are becoming significant over increased prevalent dyes of hepatitis E virus (HEV) that has increased to the level of diagnosing the problems of millions of people in every year and especially in the developing world with limited access to clean water and sanitation. Hepatitis E is an acute liver infection caused by an entity, the hepatitis E virus, which is transmitted majorly via the fecal-oral route, contaminated water, as well as food. The disease has a significant public health crisis mostly experienced in the Asian regions, in Africa, and in the Middle East as outbreak cases would be witnessed in some regions. Diagnostic tests are important in the early diagnosis, clinical control and containment of the outbreaks, which allows obtaining treatment and prevention in good time. ELISA (immunomodulatory assay) of the antibodies of IgM and IgG and molecular tests, like reverse transcription polymerase chain reaction (RT-PCR) of viral RNA detection, represent some of the most widespread types of diagnostic tests. The market is scooped by an increasing awareness of hepatitis E and the development of diagnostic procedures as well as enhancements made by the governments to enhance healthcare infrastructure. Furthermore, the use of point-of-care testing and fast diagnostic kit products is being adopted at a quicker pace in clinical and non-clinical scenarios due to the heightened demand of both types of products. There is however a poor awareness in low-income areas, inconsistencies in standardistic diagnosis procedures and low paying problems. Irrespective of these obstacles, sustained research and developments coupled with cooperation between diagnostic corporations, research centers, health providers are also likely to open the doors to growth. The market of the hepatitis E diagnostic tests is poised to the consistent growth due to the fact that the necessity of effective, fast, and affordable diagnostic testing remains to increase in the whole world.

COVID-19 IMPACT

Hepatitis E Diagnostic Tests Market Had a Negative Effect Due to Supply Chain Disruption During COVID-19 Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic had adverse effects on the hepatitis E diagnostic tests market share because it influenced the change of the healthcare priorities, health care limited diagnostic abilities, and the breakage of supply chains. A majority of the healthcare facilities including the laboratories, hospitals, and other diagnostic centers found themselves redirected by the pandemic to test and care COVID-19 during the pandemic, causing a sudden decrease in patient access to health care facilities, consequently causing late diagnosis and treatment of other pathogenic microorganisms, such as hepatitis E. Also, problems with the supply of the chain related to the supply of diagnostic kits and reagents, especially in the developing economies that were highly reliant on imports. The progress in research funding and clinical trials towards hepatitis E were also slowed by the governments and institutions concentrating on the researchers of COVID-19. In addition, campaigns on the awareness on vaccination in general and hepatitis E prevention and diagnosis were left to the background since most of the attention was paid to the pandemic preparation. Sluggish market growth and failure to roll new diagnostic products was brought about by the reduced demand during this period. Nevertheless, the pandemic also caused the issues of reinforcement of the diagnostic infrastructure and the development of the molecular testing potential that indirectly preconditions the improved use of hepatitis E diagnostic tests in the post-COVID period.

LATEST TRENDS

Consolidation & Private-Equity Rollups Are Reshaping Roofing Services Drives Market Growth

One of the current trends in the market of diagnostic tests against hepatitis E is the increased use of multiplex and point-of-care (POC) diagnostic platforms offering the possibility to test several pathogens simultaneously and provide results quickly without changing laboratory results. Elite diagnostic strategies of hepatitis E like ELISA and RT-PCR, although capable of testing and producing good results, are lengthy and need laboratory expertise unlike in resource-deficient areas. The recent technological development has resulted in journeying, simple to employ diagnostic machines, which combine hepatitis E testing with alternative hepatitis viruses and gastrointestinal infections. This is because the capability of multiplexing enhances efficient diagnostic interventions, lowers the costs of testing, and warrants prompt diagnosis during outbreak scenarios. In addition, POC devices continue to be used more frequently in rural and underserved settings with little to no access to more significant laboratories. Firms are working on both miniaturized molecular systems and lateral flow filtrations with designs that are easy to use, in addition to having very high sensitivity. COVID-19 stimulated the uptake of quick diagnostics which added further to investment in new POC solutions. As the changes in the healthcare organization and governments focus on enhancing the surveillance of infectious diseases, the adoption of the hepatitis E diagnostic tests into the multiplexes will become the guaranteed rule to introduce the changes to the market landscape, as testing will be more convenient, cost-effective, and patient-focused.

•   
•   
  

  Download Free Sample to learn more about this report

    

HEPATITIS E DIAGNOSTIC TESTS MARKET SEGMENTATION

By Type

Based on type, the global market can be categorized into ELISA HEV IgM Test kits, ELISA HEV IgG Test Kits, RT-PCR Test Kits

• ELISA HEV IgM Test Kits: These kits are meant to detect HEV IgM antibodies that are made in the event of acute infection. They are normally employed in establishing recent or current infections. Their sensitivity and specificity are very high and thus they can be used in order to be able to diagnose clinically, as well as monitor an outbreak.

• ELISA HEV IgG Test Kits: The test kits of IgG are used to detect antibodies that are presented following infection and show that one has been exposed to the hepatitis E before. They can be used to study the epidemiology or immunity. Such kits find frequent use in serological surveys on populations.

• RT-PCR Test Kits: RT-PCR kits have the capability of identifying the presence of hepatitis E viral RNA in blood or stool specimens and as such, it is considered the gold standard of getting the right diagnosis. They allow the early diagnosis prior to the development of antibodies and are of great importance to people who are at risk like pregnant women.

By Application

Based on Application, the global market can be categorized into Hospitals, Diagnostic Laboratories, Research Centers, Point of Care

• Hospitals: The main final end-users of hepatitis E diagnostic tests in the hospital are patients presenting themselves with acute liver symptoms. They are also dependent on serological and molecular tests to make the correct diagnosis. Hospitals also intervene in the tracking of an outbreak, and patient control.

• Diagnostic Laboratories: Diagnostic ecologists perform high loads of testing with Hepatitis E by criminal means of ELISA, RT-PCR. They serve hospitals as well as the public health agencies. Their intervention is essential to ensure that the results can be confirmed and they will be controlled.

• Infectious Disease Centers: Research centers apply hepatitis E diagnostic kits to investigate the epidemiology, infectiousness and regulatory lists of vaccines. There is also their contribution to innovation whereby they test hi-tech diagnostic technologies. The market development is boosted by collaborating with the industry players.

• Point of Care (POC): POC testing systems are hand-held and handheld making them easy to use and acquired hepatitis at point of care or close to it within minutes. Their benefit is that they enhance access in rural and underserved areas. They are used more conveniently and are cost effective hence their adoption is on the rise.

MARKET DYNAMICS

Driving Factors

Rising Prevalence of Hepatitis E Infections Boost the Market

The hepatitis E diagnostic tests market growth has been driven by the fact that the prevalence of hepatitis E infections in the world suffers an increasing threat. The disease is also most rampant in parts of Latin America, Asia, and Africa where the water sources are invariably unhygienic. World Health Organization (WHO) states that hepatitis E is caused when millions of hepatitis cases are observed every year which result in substantial morbidity and mortality, particularly among pregnant women. This increased disease load has necessitated a pressing demand on precise and prompt diagnostic equipment’s that would enable on time treatment and clinical control of the outbreaks. With the active promotion of early diagnosis, governments and health services are both trying to reduce the spreading and complications of diseases and increase the demand of the diagnostic kits. The increasing popularity of hepatitis E as a health concern assisted by increasing investments in medical resources, will lead to steady increases in the diagnostic market in the next few years.

Advancements in Diagnostic Technology Expand the Market

Another technological breakthrough contributing to the market of the hepatitis E diagnostic tests is the new technology that resulted in better accuracy of tests, checkups, and their access and affordability. In contemporary diagnosis, RT-PCR assays, multiplex platforms, and devices of point-of-care are applicable to increase detection limits and surpass more traditional means of detection, with the consequent maximization of detection. ELISA kits have also developed with enhanced sensitivity and specificity which enables large scale screening to take place reliably. Moreover, firms are also flooding a lot of resources towards the development of rapid diagnostic tests (RDT) and thus the process of detection of hepatitis E will be easier in resource constrained environments. The application of digital health-related projects, including mobile molecular testing devices, has additionally increased accessibility. These innovations do not only assist the management of clinical practices, but they enhance the surveillance of public health during the transgression of epidemics. As more attention is paid to decreasing turnaround times and improving patient outcomes, the further development of diagnostic technology is anticipated to boost the uptake urging the overall market growth.

Restraining Factor

Limited Awareness and Healthcare Access Potentially Impede Market Growth

However, every possibility of increasing the disease prevalence indicates that the market of hepatitis E diagnostic tests is heavily suppressed in terms of lack of awareness and accessibility to healthcare in developing countries. The affected populations are mostly ignorant about the disease, symptoms and the significance of early diagnosis leading to underreporting and late treatment. The diagnostics facilities in rural communities have been found to be poor with lack of qualified labs and absence of trained staff. Also, cheaper prices of advanced diagnostic kits including RT-PCR are still an impediment to the low-income nations. This is a contribution to the lack of knowledge and inability to access quality healthcare services which reduces the pace at which the hepatitis E diagnostic tests can be adopted in the general market hindering the growth of the overall market.

Expansion of Point-of-Care Testing Create an Opportunity for The Product in The Market

Opportunity

An increased need of the point of care (POC) diagnostic solutions serves as a huge opportunity to the market of the hepatitis E diagnostic tests. Conventional diagnostic systems that usually involve a laboratory though precise are sometimes unavailable to the people in rural or resource-deprived regions.

Providing quick, dependable as well as inexpensive testing directly on the patient care areas, POC devices enrich early identification and management of diseases. The COVID-19 pandemic increased the rate of endorsement of portable and rapid testing principles, preparing to be expanded in the diagnostics of hepatitis E.

Standardization of Diagnostic Protocols Could Be a Potential Challenge for Consumers

Challenge

The major problem that has presented in a hepatitis E diagnostic tests market is the absence of internationally integrated diagnostic procedures. Various laboratories and nations tend to use diverse testing protocols, reagents and cutoffs creating discrepancies in the results and complications in epidemiological data comparison. An example here would be that ELISA kits are common where there is a variation in the antibody cutoff point and their performance across different manufacturers.

In the same manner, RT-PCR testing is something that cannot be used broadly due to the high cost and technical expertise involved in performing the test and this leaves gaps in detection accuracy. Such failure to harmonize undermines effective surveillance, estimate disease burden and slows down approval of new products by the regulators. The solution to this issue is to work more at the international level so that to come up with standardized diagnostic guidelines, standards of validation, and quality control measures.

•   
•   
  Download Free Sample to learn more about this report

    

HEPATITIS E DIAGNOSTIC TESTS MARKET REGIONAL INSIGHTS

• North America

In North America, especially the United Sates Hepatitis E diagnostic tests market dominates the test market as the well-developed greater awareness of viral hepatitis, the presence of diagnostic firms and the adequate healthcare infrastructure is likely to take dominance of the test. Hepatitis E is comparatively not a prevalent disease in Asia and Africa but with today's trend of international travel and immigration the U.S. and Canada have been at risk of imported hepatitis e. Diagnostic abilities are also very active in the region, and ELISA and molecular tests are commonly used in hospitals and laboratories. In addition, the growth of the market is enhanced by active government targeting and funding to enhance the observation of infectious diseases. One of the major firms with headquarters in the region also invests in R&D and introducing advanced test kits to make the company stronger in the North American market.

• Europe

Another markets which are important in terms of the hepatitis E diagnostic tests involve Europe which is getting increasing cases of hepatitis E due to its connection with zoonotic infection, especially with pigs and wild animals. In other countries like Germany, France, and the UK the incidence has been emerging strengthening the demand to take a diagnostic solution. The market is well satisfied with improved public health systems, well-developed laboratory infrastructures, and a strong initiative by the government to boost the level of monitoring on viral hepatitis. Such university, laboratory and diagnostic company partnerships in Europe also lead to technology development and the growth of markets.

• Asia

Asia-Pacific controls the global diagnostic tests market in hepatitis E because of the prevalence of the disease within the territory, its occurrence, and the high number of high-risk political groups. The areas with the highest number of cases of hepatitis E are countries such as India, China, Nepal and Bangladesh, that are mostly as a result of poor sanitation and water availability. The high burden of disease has led to high demand of quality cheap diagnostic tests in the area. There is a movement amongst governments and other non-profit organizations to invest towards healthcare accessibility and infrastructure development in diagnostics. Also, there is a large number of diagnostics-kit producers in Asia, which provide the opportunity to test their solutions in low-resource-based conditions.

KEY INDUSTRY PLAYERS

Key Industry Players Shaping the Market Through Innovation and Market Expansion

The market of hepatitis E diagnostic tests is also rather competitive, as there are a number of international and local manufacturers operating in the market, dedicating their efforts to the aspects of innovations, price, and distribution coverage. The major competitors are Bio-Rad laboratories, Abbott laboratories, Beijing Wantai pharmacy biological labs, DiaSorin, Merck KGaA, QIAGEN, F. Hoffmann-La Roche Ltd. Siemens healthineers, Thermo Fisher scientific, and Mikrogen Diagnostik. Such players can provide an assortment of ELISA kits, RT-PCR tests and POC solutions to suit hospitals, laboratories and research facilities. Several firms have been working with research partners and product development to increase the accuracy and cost effectiveness of diagnostics especially in high burden locations like Asia and Africa. An example is Wantai biological HEV ELISA kits and Abbott and Roche which has been reputed as the pioneers in molecular diagnostics. Government and partnerships with NGOs are also seen as the players in the industry are concentrating on enhancing global distribution networks and engage the government and other NGOs in control of the infectious disease. The threat of substitutes posed by new and evolving breakthroughs, regulatory licensing, and service moves to implement hepatitis E testing in multiplex test kits would also guarantee that the market growth is sustained.

List Of Top Hepatitis E Diagnostic Tests Market Companies

• Chemeurope (Germany)
• Wantai Biological (China)
• Biokit (Spain)
• Pro Diagnostic Bioprobes (Italy)

KEY INDUSTRY DEVELOPMENT

June 2023: Abbott Laboratories Announced expansion of its infectious disease testing portfolio by launching new ELISA-based hepatitis panels, including HEV detection, in Asian markets.

REPORT COVERAGE

The hepatitis E diagnostic tests market is set to experience a tremendous growth, owing to the rising burden of the disease in the world, the development of the diagnostic techs and the increasing awareness among the people about their health. The need to find timely and precise testing has never been so much felt as millions of new cases of hepatitis E are taking place every year especially in Asia and Africa. ELISA IgM and IgG detection kits, RT-PCR and assays continue to be the foundation of diagnostic solutions, with new point-of-care and multiplex platforms continuing to increase accessibility to underserved populations. Despite current obstacles which include little awareness, ample profitable partnerships, and present financial constraints, there is an increasing investment on healthcare facilities and cross-border partnerships that are increasingly clearing the way towards market growth. Areas like North America and Europe are playing their roles in technological innovation and research whereas Asia-Pacific is the biggest market on the basis of the high prevalence of the disease. The main actors in the industry are Moscotting at product innovation, alliances and distribution development to ensure that they are competitive. According to the recent changes in the context of recent diagnose changes, there is an increasing tendency to use a quick, delicate, and mobile diagnostic equipment, which will prove crucial in managing elevations and controlling the disease. On the whole, the hepatitis E diagnostic services market has a high potential, and the possibility of sustainable development due to the increase in the role that the global healthcare systems attach to the preparation and prevention of infectious diseases.